🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants

RecruitingPhase 4Ages 24 Weeks - 29 WeeksAllAristotle University Of Thessaloniki
NCT07652684 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Infants born at Papageorgiou Hospital in Neonatology Department and NICU of Aristotle University of Thessaloniki with GA equal to or less than 29 weeks are eligible to participate in the study. Exclusion Criteria: Congenital malformations, chromosomal abnormalities or critical illness with short life expectancy. Study participation requires written informed parental consent within 48h after birth.
💊

What it tests

  • Enteral supplementation with ARA and DHA (in a 2:1 ratio) in addition to standard care and feeding
  • Standard care and feeding
📍

Where

1 site
Papageorgiou General Hospital
Thessaloniki, Greece
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy